AUS
NZ
UK
CA
USA
IND
Highlights
- Emi-Le demonstrated a 23% objective response rate in B7-H4 high tumors at intermediate doses.
- No Grade 4 or 5 treatment-related adverse events were observed during the Phase 1 trial.
- Mersana's differentiated safety profile with limited severe complications from ADCs stood out.
Mersana Therapeutics (NASDAQ:MRSN) has revealed promising initial clinical data from its ongoing Phase 1 trial of emiltatug ledadotin (Emi-Le), a novel antibody-drug conjugate (ADC) designed to target B7-H4 in cancer treatment. The Phase 1 trial enrolled a cohort of 130 patients, all with advanced or metastatic cancers, including a significant number of patients with triple-negative breast cancer (TNBC), a notoriously difficult cancer to treat.
The early findings from the trial show a significant level of promise for Emi-Le. The trial enrolled patients who had received prior therapies, including those with advanced stages of cancer, showcasing the drug's potential as a treatment option for patients with few remaining alternatives. The treatment was generally well tolerated, with no Grade 4 or 5 treatment-related adverse events, which is a positive sign for the future of this therapy.
One of the standout findings from the study is the 23% confirmed objective response rate (ORR) at intermediate doses (38.1-67.4 mg/m2) among B7-H4 high tumors and TNBC patients who had previously been treated with topoisomerase 1 (Topo-1) ADCs. This early success is noteworthy because it highlights the potential for Emi-Le to treat cancers that are resistant to previous therapies.
In addition to the promising response rate, the drug's safety profile stands out as well. No significant or life-threatening adverse events were reported, including the common severe complications often associated with other ADC therapies. There were no dose-limiting neutropenia, neuropathy, ocular toxicity, or thrombocytopenia, which are some of the severe side effects that typically accompany similar treatments.
However, the trial did face some challenges. Higher doses of the treatment, specifically those above 76 mg/m2, required protocol-mandated dose delays due to instances of proteinuria, a condition where excess protein is found in the urine. This delayed confirmation of responses at the higher dose levels, and at these doses, only 2 of the 9 patients (22%) achieved confirmed responses, which suggests the need for further dose optimization in future trials.
Despite these hurdles, the results from the Phase 1 trial are encouraging, with 78% of patients receiving the higher doses showing a tumor reduction of at least 30%. This result strengthens the case for continued development of Emi-Le in cancer treatment, especially in the context of cancers that are difficult to treat with existing therapies.
Looking forward, Mersana has already initiated an expansion phase of the trial, particularly focusing on TNBC patients at the 67.4 mg/m2 dose level. This expansion is expected to provide more data and help further refine the treatment’s therapeutic potential.
